Komori
Earnings presentation4971MEC COMPANY LTD.Materials and Chemicals

2023年12月期第2四半期決算説明会資料

2023年12月期第2四半期は、半導体市況の調整や個人消費の停滞などで、売上高・営業利益とも前年同期を大きく下回った。出荷量も減少した一方、為替は円換算ベースで増収・増益要因となった。

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
23.7
% decrease (year-on-year change in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Earnings presentation2023年12月期 第2四半期13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6,198 million-23.7%
Operating profit¥838 million-59.8%
Ordinary income¥1,003 million-57.7%
Net income¥1,076 million-35.2%
Selling, general and administrative expenses¥2,807 million
Gross Profit Margin
Rate58.8%
Operating profit margin
Rate13.5%
Results for the three months of the current quarter2023年4-6月単独で、売上高3,432百万円、営業利益669百万円、営業利益率19.5%。品種別売上は薬品3,372百万円、機械31百万円、資材27百万円、その他1百万円。
Full-year earnings forecast
Net Sales
¥13,500 million
Operating profit
¥1,800 million
Ordinary income
¥1,900 million
Net income
¥1,730 million
Earnings per share
¥91.89
Dividend per share
¥45
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales45.9%
Operating profit46.6%
Ordinary income52.8%
Net income62.2%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
連結売上高は密着向上剤、エッチング剤、その他薬品、機械、資材、その他売上、為替の影響に分解。連結営業利益は薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）に分解。個別要因の金額はNot disclosed。
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD¥4.37
RMB¥19.33
HKD¥16.34
THB¥3.69
EUR¥136.04
USD¥128.03
前提説明いずれも期中平均レート。
New initiatives
  • Creation of New Businesses
  • 既存技術の応用展開
  • 化学密着向上剤APシリーズの展開
Key KPIsA metric the company considers important as a management benchmark.
  • 薬品出荷量16,055 t
    Year on year against the same period last yearDown 30.6%
  • Overseas revenue ratio61.5%
    Year on year against the same period last year前年同一期間61.2%から増加
  • 国内代理店販売分を含む海外売上高比率77.8%
    前年同一期間比79.4%
  • R&D expenses as a percentage of revenue11.1%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
薬品出荷量16,055t（前年同期比30.6%減）が示されているが、単価はNot disclosed。
Segment results
地域別売上高（2023年4-6月単独）
Japan
¥1,376 million
Taiwan
¥589 million
China
¥1,081 million
Europe
¥240 million
Thailand
¥143 million
Medium-term management plan targets
Consolidated payout ratio30%
ROE2024年10%以上
Financial targets
ROE
Target2024年10%以上
Track Record2022年12月期13.8%
Number of employees
Number of Employees連結438名、単体253名
As of2022年12月31日現在
Capital expenditures
グラフ掲載あり
Annual Dividend
Annual¥45.0
Interim¥20.0
End of period¥25.0 per share
Payout ratio
2023年12月期予想49.0%、中期目標30%
Acquisition of treasury shares
Acquisition period2023年5月11日〜2023年6月23日
Total number of shares acquired286,000株
Total acquisition price899,860,700円
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period Covered2023年12月期 第2四半期
Net Sales¥6,198 million (YoY -23.7%)
Operating profit¥838 million (YoY -59.8%)
Ordinary income¥1,003 million (YoY -57.7%)
Net income¥1,076 million (YoY -35.2%)
Gross Profit MarginRate 58.8% / Year-on-year change (points) Not disclosed
Operating profit marginRate 13.5% / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses¥2,807 million
Results for the three months of the current quarter2023年4-6月単独で、売上高3,432百万円、営業利益669百万円、営業利益率19.5%。品種別売上は薬品3,372百万円、機械31百万円、資材27百万円、その他1百万円。
Full-year earnings forecastNet Sales ¥13,500 million / Operating profit ¥1,800 million / Ordinary income ¥1,900 million / Net income ¥1,730 million / Earnings per share ¥91.89 / Dividend per share ¥45
Progress against full-year forecastNet Sales 45.9% / Operating profit 46.6% / Ordinary income 52.8% / Net income 62.2%
Segment results地域別売上高（2023年4-6月単独） Japan ¥1,376 million / Taiwan ¥589 million / China ¥1,081 million / Europe ¥240 million / Thailand ¥143 million
Breakdown of Factors Affecting the Change連結売上高は密着向上剤、エッチング剤、その他薬品、機械、資材、その他売上、為替の影響に分解。連結営業利益は薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）に分解。個別要因の金額はNot disclosed。
Key KPIsIndicator name 薬品出荷量 / Value 16,055 t / Year on year against the same period last year Down 30.6%, Indicator name Overseas revenue ratio / Value 61.5% / Year on year against the same period last year 前年同一期間61.2%から増加, Indicator name 国内代理店販売分を含む海外売上高比率 / Value 77.8% / 前年同一期間比 79.4%, Indicator name R&D expenses as a percentage of revenue / Value 11.1% / Year on year against the same period last year Not disclosed
Unit price and quantity metrics薬品出荷量16,055t（前年同期比30.6%減）が示されているが、単価はNot disclosed。
Number of employeesNumber of Employees 連結438名、単体253名 / As of 2022年12月31日現在 / Changes during the period and hiring plan Not disclosed
Assumptions Underlying the Business OutlookExchange rate NTD ¥4.37 / RMB ¥19.33 / HKD ¥16.34 / THB ¥3.69 / EUR ¥136.04 / USD ¥128.03 / 前提説明 いずれも期中平均レート。
Medium-term management plan targetsConsolidated payout ratio 30% / ROE 2024年10%以上
Financial targetsROE Target 2024年10%以上 / Track Record 2022年12月期13.8%
Annual DividendAnnual ¥45.0 / Interim ¥20.0 / End of period ¥25.0 per share
Payout ratio2023年12月期予想49.0%、中期目標30%
Acquisition of treasury sharesAcquisition period 2023年5月11日〜2023年6月23日 / Total number of shares acquired 286,000株 / Total acquisition price 899,860,700円
Capital expendituresグラフ掲載あり
New initiativesCreation of New Businesses, 既存技術の応用展開, 化学密着向上剤APシリーズの展開
Items this document does not state (6)
Self-assessment against the planNumber of stores and locationsRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

会社は、半導体市況の調整、個人消費の停滞、ディスプレイ在庫調整、スマートフォン向け需要の低迷などを短期的な影響として挙げている。また、薬品出荷量が前年同期比30.6%減少した。為替は売上高152百万円増、営業利益59百万円増の要因となった。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
2023年12月期第2四半期決算説明会資料 | MEC COMPANY LTD. (4971) timely disclosure | Komori